申联生物(688098) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥78,741,129.63, representing a decrease of 10.58% compared to ¥88,058,162.67 in the same period last year[4]. - The net profit attributable to shareholders was -¥3,019,866.61, while the net profit after deducting non-recurring gains and losses was -¥4,450,133.90, indicating a continued loss[4]. - Net profit for Q1 2025 was a loss of ¥4,054,605.47, compared to a loss of ¥3,125,388.59 in Q1 2024, representing a 29.7% increase in loss[18]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.01, unchanged from Q1 2024[19]. - Cash received from sales and services in Q1 2025 was ¥34,850,686.15, down 30.9% from ¥50,460,078.65 in Q1 2024[20]. Cash Flow - The net cash flow from operating activities was -¥28,560,955.60, compared to -¥24,404,381.56 in the same period last year, indicating a worsening cash flow situation[4]. - Cash flow from operating activities for Q1 2025 was a net outflow of ¥28,560,955.60, compared to a net outflow of ¥24,404,381.56 in Q1 2024[20]. - Net cash flow from investment activities was $15,648,403.65, a decrease from $20,450,214.15 in the previous period, reflecting a decline of approximately 23.5%[21]. - The net increase in cash and cash equivalents was -$14,827,032.87, compared to -$4,035,094.87, indicating a decline of about 267%[21]. - The ending balance of cash and cash equivalents was $96,342,060.93, down from $40,805,615.51, reflecting a decrease of approximately 136%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,560,660,343.91, a slight increase of 0.42% from ¥1,554,117,949.14 at the end of the previous year[5]. - Total liabilities as of the end of Q1 2025 were ¥140,772,376.01, an increase from ¥128,495,487.08 at the end of Q1 2024[16]. - The company's cash and cash equivalents decreased to RMB 96,483,629.97 from RMB 146,206,489.54 in the previous period, representing a decline of approximately 34%[12]. - Accounts receivable increased to RMB 302,159,319.19, up from RMB 261,397,654.93, indicating a growth of about 15.6%[12]. - The total non-current assets reached RMB 1,018,721,546.88, slightly up from RMB 1,003,287,152.99, showing a modest increase of about 1.8%[13]. Research and Development - Research and development expenses totaled ¥14,871,393.62, which is an increase of 4.84% from ¥14,184,983.93 in the previous year, accounting for 18.89% of operating revenue, up from 16.11%[4][5]. - Research and development expenses for Q1 2025 were ¥11,111,043.54, a decrease of 12.1% from ¥12,646,826.27 in Q1 2024[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,892[8]. - The largest shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares[9]. - UNITED BIOMEDICAL, INC. holds 10.52% of the shares, totaling 43,199,898 shares, with a portion of shares frozen[9]. Other Information - The company continues to focus on cost control and optimizing R&D resources despite the decline in revenue[7]. - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[11].